Trulieve: Analysts Expect Beat On Company Full Year Guidance

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 23rd. Analysts have a consensus C$65.83 12-month price target on the company, via a total of 14 analysts, with two analysts have strong buy ratings and the other 12 have buy ratings. The street high comes from Stifel-GMP with a C$107 price target, and the lowest target comes from Echelon Wealth with a C$43 price target.

Twelve analysts have revenue estimates for the fourth quarter. The mean between all 12 is U$162.49 million; this number has been revised upwards from U$159.35 million at the start of the year. Stifel-GMP currently has the highest revenue estimate with U$170.87 million, while the lowest comes from PI Financial with a U$153.25 estimate.

For the full year, management has guided for revenues between U$465 – U$485 million, but the average estimate between 14 analysts is currently U$513.59 million. This number has been revised upwards from U$511.55 million at the start of the year. The street high comes from Stifel-GMP with a U$523.95 full-year revenue estimate.

Onto EBITDA estimates, there are currently 12 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$75.56 million, with this number being revised upwards from U$72.46 million at the start of the year. Street high goes to Needham with a U$81.30 million EBITDA estimate and the lowest being PI Financial with a U$68.87 million estimate.

For the full-year management has also provided guidance for EBITDA in the range of U$205 – U$225 million. The current EBITDA means across 13 analysts is U$252.47 million, with that number basically staying flat year-to-date. Needham currently has the highest full-year estimate at U$258.80 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Gold & Copper Stocks Everyone Keeps Asking About | Oct. 12-16 – Weekly Mining Mailbag

Similar Gold Mines Are Valued 10X Higher. Why Not This One? | JW Dumont – Granada Gold Mine

The US Interest Bill Gold Can’t Ignore | Peter Grandich

Recommended

Blue Jay Gold Signs Ocean Partners Deal to Ship Steller Stockpiles Through 2027

Krait Critical Minerals Signs Option for Historical Nevada King Antimony Mine

Related News

Trulieve Cannabis: Analyst Q1 Consensus Estimates

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their first quarter financials before...

Wednesday, May 12, 2021, 04:01:00 PM

Trulieve Closes Oversubscribed $115.5 Million Financing

Trulieve Cannabis (CSE: TRUL) has closed its previously announced private placement, raising gross proceeds of...

Monday, September 21, 2020, 09:14:40 AM

Haywood Reiterates $80 Price Target On Trulieve After Harvest Health Purchase

On October 1st, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition...

Monday, October 11, 2021, 04:43:00 PM

Trulieve Sees Canaccord Maintain $35 Price Target Days Before Share Unlock

Trulieve Cannabis (CSE: TRUL) this morning saw Canaccord Genuity reaffirm its speculative buy rating on...

Wednesday, May 13, 2020, 11:20:52 AM

Trulieve Prices Public Offering At C$198.1 Million

Trulieve Cannabis (CSE: TRUL) this evening released the pricing of their previously announced public offering...

Wednesday, April 7, 2021, 08:26:04 PM